Lorazepam

Generic Name
Lorazepam
Brand Names
Ativan, Loreev
Drug Type
Small Molecule
Chemical Formula
C15H10Cl2N2O2
CAS Number
846-49-1
Unique Ingredient Identifier
O26FZP769L
Background

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication

Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
...

Associated Conditions
Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
Associated Therapies
Anesthetic premedication therapy
Clinical Trials
Related News

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

Phase 1
Completed
Conditions
Healthy Subjects
First Posted Date
2007-01-19
Last Posted Date
2010-10-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
26
Registration Number
NCT00424697
Locations
🇺🇸

GSK Investigational Site, La Jolla, California, United States

SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia

Phase 1
Terminated
Conditions
Schizophrenia
First Posted Date
2006-08-15
Last Posted Date
2016-01-11
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
55
Registration Number
NCT00364429
Locations
🇪🇸

GSK Investigational Site, Barcelona, Spain

Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.

Phase 3
Terminated
Conditions
Convulsions
Status Epilepticus
First Posted Date
2006-06-22
Last Posted Date
2012-07-10
Lead Sponsor
Kamuzu University of Health Sciences
Target Recruit Count
800
Registration Number
NCT00343096
Locations
🇲🇼

Queen Elizabeth Central Hospital, Paediatric Dept, Box 360, Blantyre, Malawi

Treatment of Alcohol Withdrawal in Hospital Patients

First Posted Date
2005-11-07
Last Posted Date
2016-04-11
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
183
Registration Number
NCT00249366
Locations
🇺🇸

Virginia Commonwealth University Medical Center, Richmond, Virginia, United States

Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam

Phase 2
Completed
Conditions
Alcohol Withdrawal Syndrome(AWS)
First Posted Date
2005-09-29
Last Posted Date
2005-09-29
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Target Recruit Count
160
Registration Number
NCT00229125
Locations
🇺🇸

Medical University of South Carolina - Center for Drug and Alcohol Programs, Charleston, South Carolina, United States

Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects

Phase 4
Completed
Conditions
Sedation
First Posted Date
2005-09-12
Last Posted Date
2008-10-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
224
Registration Number
NCT00158873
Locations
🇳🇱

GSK Investigational Site, Zwolle, Netherlands

GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1

First Posted Date
2005-07-25
Last Posted Date
2016-05-12
Lead Sponsor
University of California, Los Angeles
Registration Number
NCT00123578
Locations
🇺🇸

UCLA, Los Angeles, California, United States

Lorazepam for the Treatment of Status Epilepticus in Children

Phase 1
Completed
Conditions
Status Epilepticus
First Posted Date
2005-06-16
Last Posted Date
2016-05-23
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Target Recruit Count
69
Registration Number
NCT00114569
Locations
🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

Lorazepam Sedation for Critically Ill Children

First Posted Date
2005-04-28
Last Posted Date
2023-03-20
Lead Sponsor
The Emmes Company, LLC
Target Recruit Count
179
Registration Number
NCT00109395
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status

Phase 2
Completed
Conditions
Delirium
Interventions
Drug: Dexmedetomidine
Drug: Lorazepam
First Posted Date
2004-11-02
Last Posted Date
2018-09-11
Lead Sponsor
Vanderbilt University
Target Recruit Count
100
Registration Number
NCT00095251
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy